BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9756944)

  • 1. Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2.
    Crovello CS; Lai C; Cantley LC; Carraway KL
    J Biol Chem; 1998 Oct; 273(41):26954-61. PubMed ID: 9756944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases.
    Carraway KL; Weber JL; Unger MJ; Ledesma J; Yu N; Gassmann M; Lai C
    Nature; 1997 May; 387(6632):512-6. PubMed ID: 9168115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligands for ErbB-family receptors encoded by a neuregulin-like gene.
    Chang H; Riese DJ; Gilbert W; Stern DF; McMahan UJ
    Nature; 1997 May; 387(6632):509-12. PubMed ID: 9168114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist.
    Wilson KJ; Mill CP; Gallo RM; Cameron EM; VanBrocklin H; Settleman J; Riese DJ
    Biochem J; 2012 Apr; 443(1):133-44. PubMed ID: 22216880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors.
    Sweeney C; Fambrough D; Huard C; Diamonti AJ; Lander ES; Cantley LC; Carraway KL
    J Biol Chem; 2001 Jun; 276(25):22685-98. PubMed ID: 11297548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand discrimination in signaling through an ErbB4 receptor homodimer.
    Sweeney C; Lai C; Riese DJ; Diamonti AJ; Cantley LC; Carraway KL
    J Biol Chem; 2000 Jun; 275(26):19803-7. PubMed ID: 10867024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.
    Waterman H; Alroy I; Strano S; Seger R; Yarden Y
    EMBO J; 1999 Jun; 18(12):3348-58. PubMed ID: 10369675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding specificities and affinities of egf domains for ErbB receptors.
    Jones JT; Akita RW; Sliwkowski MX
    FEBS Lett; 1999 Mar; 447(2-3):227-31. PubMed ID: 10214951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The N-terminal domains of neuregulin 1 confer signal attenuation.
    Warren CM; Kani K; Landgraf R
    J Biol Chem; 2006 Sep; 281(37):27306-16. PubMed ID: 16825199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.
    Schaefer G; Fitzpatrick VD; Sliwkowski MX
    Oncogene; 1997 Sep; 15(12):1385-94. PubMed ID: 9333014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4.
    Higashiyama S; Horikawa M; Yamada K; Ichino N; Nakano N; Nakagawa T; Miyagawa J; Matsushita N; Nagatsu T; Taniguchi N; Ishiguro H
    J Biochem; 1997 Sep; 122(3):675-80. PubMed ID: 9348101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase.
    Hobbs SS; Cameron EM; Hammer RP; Le AT; Gallo RM; Blommel EN; Coffing SL; Chang H; Riese DJ
    Oncogene; 2004 Jan; 23(4):883-93. PubMed ID: 14661053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4.
    Zhang D; Sliwkowski MX; Mark M; Frantz G; Akita R; Sun Y; Hillan K; Crowley C; Brush J; Godowski PJ
    Proc Natl Acad Sci U S A; 1997 Sep; 94(18):9562-7. PubMed ID: 9275162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bivalence of EGF-like ligands drives the ErbB signaling network.
    Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y
    EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta.
    Riese DJ; Bermingham Y; van Raaij TM; Buckley S; Plowman GD; Stern DF
    Oncogene; 1996 Jan; 12(2):345-53. PubMed ID: 8570211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuregulins are concentrated at nerve-muscle synapses and activate ACh-receptor gene expression.
    Jo SA; Zhu X; Marchionni MA; Burden SJ
    Nature; 1995 Jan; 373(6510):158-61. PubMed ID: 7816098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase.
    Harari D; Tzahar E; Romano J; Shelly M; Pierce JH; Andrews GC; Yarden Y
    Oncogene; 1999 Apr; 18(17):2681-9. PubMed ID: 10348342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neuregulin-I/ErbB signaling system in development and disease.
    Britsch S
    Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
    Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events.
    Gilmore JL; Gallo RM; Riese DJ
    Biochem J; 2006 May; 396(1):79-88. PubMed ID: 16445385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.